Belite Bio is a clinical stage biopharmaceutical company dedicated to developing innovative therapies for patients with retinal degenerative eye diseases. With a focus on addressing unmet medical needs, we strive to bring hope and improved health outcomes to those suffering from conditions like atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease. Our lead candidate, Tinlarebant, is a novel oral therapy developed from our RBP4 intellectual property portfolio.

It aims to reduce the accumulation of toxins in the eye that cause Stargardt disease and contribute to geographic atrophy. Currently, Tinlarebant is undergoing a two-year Phase 2 study for Stargardt disease and is enrolling patients for a Phase 3 study (DRAGON) in adolescent subjects. Additionally, we are planning to commence a Phase 3 study (PHOENIX) for geographic atrophy in mid-2023.

We are proud that Tinlarebant has received Fast Track, Rare Pediatric Disease, and Orphan Drug designations in both the U. S. Join us at Belite Bio in our mission to treat the untreatable and transform the lives of patients suffering from blindness, liver disease, and diabetes.

Contact us today for more information about our promising pipeline of therapies